Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GNPS - 16 mzXML trial Shimadzu with raw .lcd file and mzXML converted with MSConvet (peak picking level 1-2, 32-bit, no compression)

ABSTRACT: 16 mzXML trial Shimadzu with raw .lcd file and mzXML converted with MSConvet (peak picking level 1-2, 32-bit, no compression)

INSTRUMENT(S): Shimadzu 9030 QTOF

ORGANISM(S): Streptomyces Sp.

SUBMITTER: Nataliia Machushynets

PROVIDER: MSV000084197 | GNPS | Mon Aug 12 01:38:00 BST 2019

REPOSITORIES: GNPS

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

16 mzXML trial Shimadzu with raw .lcd file and mzXML converted with MSConvet (peak picking level 1-2, 32-bit, no compression)

Project description:16 mzXML trial Shimadzu with raw .lcd file and mzXML converted with MSConvet (peak picking level 1-2, 32-bit, no compression)

2019-08-12 | MSV000084197 | MassIVE

Trial

Project description:Trial Trial

| PRJEB7892 | ENA

SOD cambium Proteomics Data - OnPLS integration of transcriptomic, proteomic and metabolomic data shows multi-level oxidative stress responses in the cambium of transgenic hipI- superoxide dismutase Populus plants

Project description:Reactive oxygen species (ROS) are involved in the regulation of diverse physiological processes in plants, including various biotic and abiotic stress responses. Thus, oxidative stress tolerance mechanisms in plants are complex, and diverse responses at multiple levels need to be characterized in order to understand them. The MS raw data files were converted to mzXML files using massWolf (version 4.3.1). The MS mzXML and MASCOT xml files were parsed and processed with a program developed in-house. Briefly, each scan was subjected to smoothing using Savitzky-Golay filtering (second order polynomial, five data points, two iterations) and peak areas were calculated after noise reduction. Peak mass was set to the average of the three highest data points for each peak. Unique peptides identified with MASCOT were matched to the parsed MS data using the parameters detected m/z, charge state and retention time, using a retention time window of ± 1.0 min. Charge states were calculated by using the first three isotopic peaks of a peptide and the same mass tolerances for detecting the mono isotopic peak as in the MASCOT search.

2014-04-17 | PXD000532 | Pride

Genome-Wide Profiling of Airway Epithelial Cells in Asthmatics, Smokers and Healthy Controls

Project description:We collected airway epithelial brushings for microarray analysis from 42 asthmatics and two control groups – 28 healthy subjects and 16 smokers. A subgroup of 32 asthmatics completed a randomized placebo-controlled trial of fluticasone propionate in which collection of brushings was repeated after 1 week of treatment. Keywords: disease state analysis, clinical trial

2007-10-12 | GSE4302 | GEO

The NEWEST trial

Project description:The NEWEST (Neoadjuvant Endocrine Therapy for Women with Estrogen-Sensitive Tumours) trial compared the clinical and biological activity of fulvestrant 500 mg vs 250 mg in the neoadjuvant setting. In this multi-centre phase II study, post-menopausal women with operable, locally advanced (T2, 3, 4b; N0-3; M0) ER-positive breast tumours were randomised to receive neoadjuvant treatment with either dose of fulvestrant for 16 weeks before surgery. Tumour core biopsies were obtained at baseline, 4 weeks and at surgery for assessment of changes in biomarker expression. Tumour volumes were measured by 3-D ultrasound at the same timepoints. In this trial, the percentage of patients who showed a reduction in tumour volume or stabilisation of disease (using RECIST criteria) after treatment with fulvestrant 500 mg was 36% (26 out of 69 patients). Therefore, within a population of endocrine-therapy naive patients whose tumours were confirmed as being ER-positive at the time of study entry, there is a subgroup who gained particular clinical benefit from fulvestrant treatment. These clinical response data together with the availability of biological response information and frozen tumour tissue from participants makes the NEWEST trial an attractive setting in which to investigate the potential of new markers of response to fulvestrant. 42 samples

2014-01-08 | E-GEOD-48905 | biostudies-arrayexpress

ExcludeMRSA-trial

Project description:ExcludeMRSA-trial

| PRJEB79374 | ENA

Virome Trial

Project description:Virome trial

| PRJEB63599 | ENA

The NEWEST trial

2014-01-08 | GSE48905 | GEO

Dietary protein in vitro digest (LC-MS)

Project description:16 dietary protein preparations were digested according to a standardized invitro digestion (InfoGest) protocol, simulating gastrointestinal digestion. Resulting oligopeptide mixtures were subsequently analyzed by UPLC-MS using DDA shot-gun detection. Peak intensity data from MS1 spectra were obtained using Progenesis QI. MS1 peak data were matched and filtered based on overlap with the reference digest of Whey protein using a custom made script in R. MSMS fragmentation spectra were converted to .mgf format and de novo interpreted using SearchGUI 3.3.17 and RapidNOVOR algorithm. Raw data, peak intensity tables and de novo interpretaion data are provided.

2021-09-09 | PXD021577 | Pride

Trial B 2019

Project description:Trial B 2019

| PRJEB32732 | ENA